Pilot dose-response trial of I.V. ketamine in treatment-resistant depression

World Journal of Biological Psychiatry

Volumn 15, Issue 7, 2014, Pages 579-584

  Lai, Rosalyn ^a   Katalinic, Natalie ^b   Glue, Paul ^c   Somogyi, Andrew A ^d   Mitchell, Philip B ^b,e   Leyden, John ^f   Harper, Simon ^g   Loo, Colleen K ^b,e,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e BLACK DOG INSTITUTE   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h WESLEY HOSPITAL   (Australia)

Author keywords

Depression; Dose response relationship; Drug related side effects and adverse reactions; Intravenous administration; Ketamine

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANXIETY; ARTICLE; CASE REPORT; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION RESPONSE; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; ORAL PARESTHESIA; PHOBIA; PILOT STUDY; RESTLESSNESS; SEDATION; SELF CONCEPT; SIDE EFFECT; TACHYCARDIA; TRANSIENT TACHYCARDIA; TREATMENT RESISTANT DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 84907260750     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2014.922697     Document Type: Article

References (20)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
2. Brass EP. 2010. The gap between clinical trials and clinical practice: The use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 87: 351-355.
3. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. 1998. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136.
4. Clyde DJ. 1986. SAFTEE: Data system for side effect assessment scale. Psychopharmacol Bull 22: 287.
5. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. 2010. A randomized add-on trial of an N-methyl-D-Aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
6. Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ. 2009. A multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry 70: 177-184.
7. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology . Rockville, MD: Department of Health, Eduation, and Welfare.
8. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr. 2011. Rapid decrease in depressive symptoms with an N-methyl-d-Aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 1155-1159.
9. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. 2013. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Aust NZ J Psychiatry 47: 710-727.
10. Larkin GL, Beautrais AL. 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14: 1127-1131.
11. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
12. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomised controlled trial. Am J Psychiatry 170: 1134-1142.
13. Posvar EL, Sedman AJ. 1989. New drugs: Fi rst time in man. J Clin Pharmacol 29: 961-966.
14. Rose D, Fleischmann P, Wykes T, Leese M, Bindman J. 2003. Patientsperspectives on electroconvulsive therapy: Systematic review. Br Med J 326: 1363.
15. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. 2003. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573-583.
16. Shafer A. 2005. Meta-Analysis of the brief psychiatric rating scale factor structure. Psychol Assess 17: 324-335.
17. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, et al. 2011. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191: 122-127.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.
19. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. 2012. Replication of ketamines antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71: 939-946.
20. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. 2006. A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.